Scinai Immunotherapeutics Ltd. Updates Shareholder Meeting Proxy
Ticker: SCNI · Form: 6-K · Filed: Aug 5, 2024 · CIK: 1611747
| Field | Detail |
|---|---|
| Company | Scinai Immunotherapeutics Ltd. (SCNI) |
| Form Type | 6-K |
| Filed Date | Aug 5, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, proxy-update, filing
Related Tickers: SCNI
TL;DR
Scinai (SCNI) updated its proxy for the Aug 12 shareholder meeting. Check the new docs.
AI Summary
Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) filed a Form 6-K on August 5, 2024, to provide a Notice to Shareholders regarding changes to its Proxy Statement. This notice pertains to the company's Extraordinary Meeting of Shareholders scheduled for Monday, August 12, 2024.
Why It Matters
Shareholders need to be aware of updated proxy materials before voting at the upcoming Extraordinary Meeting of Shareholders.
Risk Assessment
Risk Level: low — This filing is an update to proxy materials for an upcoming shareholder meeting and does not represent a significant change in business operations or financial standing.
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Filer
- BiondVax Pharmaceuticals Ltd. (company) — Former company name
- August 5, 2024 (date) — Filing date
- August 12, 2024 (date) — Extraordinary Meeting of Shareholders date
FAQ
What is the purpose of the Form 6-K filing?
The Form 6-K filing is to attach a Notice to Shareholders containing changes to the Proxy Statement for the company's Extraordinary Meeting of Shareholders.
When is the Extraordinary Meeting of Shareholders scheduled to take place?
The Extraordinary Meeting of Shareholders is scheduled for Monday, August 12, 2024.
What was Scinai Immunotherapeutics Ltd. formerly known as?
Scinai Immunotherapeutics Ltd. was formerly known as BiondVax Pharmaceuticals Ltd.
What specific document is attached as Exhibit 99.1?
Exhibit 99.1 is a notice to the Company's shareholders containing changes to the Proxy Statement.
Under which rule is this Report of Foreign Private Issuer filed?
This report is filed pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934.
Filing Stats: 294 words · 1 min read · ~1 pages · Grade level 10.8 · Accepted 2024-08-05 17:29:33
Filing Documents
- ea0210633-6k_scinai.htm (6-K) — 12KB
- ea021063301ex99-1_scinai.htm (EX-99.1) — 50KB
- 0001213900-24-065259.txt ( ) — 63KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: August 5, 2024 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 3